Dr. Cooreman most recently served as a Senior Translational Medicine Expert, Autoimmune Diseases and Transplantation, Exploratory Clinical Development at Novartis. Prior to joining Novartis in 2003, Michael spent almost ten years in academic medicine, with appointments including Associate Professor of Medicine and Staff Gastroenterologist at the University of Amsterdam in The Netherlands and as Visiting Scientist at Mt. Sinai School of Medicine, Department of Liver Diseases, in New York City. Earlier in his career, he spent two years as Head of Clinical Research and Development, Gastroenterology and Oncology at Janssen Pharmaceuticals in Germany. Michael received certification in Germany in Internal Medicine, Gastroenterology and Hepatology, earned an M.D. at the University of Leuven Medical School, Belgium, and a doctorate at the University of Dusseldorf, Germany.
About Ikaria Holdings, Inc.
Ikaria Holdings, Inc. is a fully integrated biotherapeutics company
focused on the development and commercialization of innovative
pharmaceutical and biological products and drug/device combinations for the
critically ill in the hospital and ICU setting. The company's product,
INOmax(R) (nitric oxide) for inhalation, is an FDA-approved drug for the
treatment of hypoxic respiratory failure in term and near-term newborns.
|SOURCE Ikaria Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved